Citations

Showing 10 of 108152 citations.

Osteolytic lesions in myelofibrosis
Johnson, Isla McKerrow , Johnson, Isla , Alkhateeb, Hassan B.

Mayo Clinic

Clinical Case Reports | July 19, 2021 | Volume: 9 | Issue: 7 | Pages: No page available

10.1002/ccr3.4276 | PMID 34295475 Get It

Abstract Bony pain in patients with a history of myelofibrosis warrants further investigation. Although skeletal involvement in myelofibrosis is more commonly osteosclerosis or periostitis, it can also cause osteolytic lesions.
Does early activation within hours after cochlear implant surgery influence electrode impedances?
Saoji, Aniket A. , Adkins, Weston J., Graham, Madison K., Carlson, Matthew L.

Mayo Clinic

International Journal of Audiology | July 18, 2021 | Volume: 61 | Issue: 6 | Pages: 520-525

10.1080/14992027.2021.1942569 | PMID 34278935 Get It

Systematic review with meta‐analysis: neoplasia detection rate and post‐endoscopy Barrett's neoplasia in Barrett's oesophagus
Hamade, Nour , Kamboj, Amrit K. , Krishnamoorthi, Rajesh , Singh, Siddharth , Hassett, Leslie C. , Katzka, David A. , Kahi, Charles J. , Fatima, Hala , Iyer, Prasad G. , Hassett, Leslie C

Mayo Clinic

Alimentary Pharmacology & Therapeutics | July 18, 2021 | Volume: 54 | Issue: 5 | Pages: 546-559

10.1111/apt.16531 | PMID 34275161 Get It

SummaryBackgroundNeoplasia detection rate, the proportion of Barrett's oesophagus patients with high‐grade dysplasia or oesophageal adenocarcinoma detected at index surveillance endoscopy has been proposed as a quality metric. However, the correlation between neoplasia detection rate and a clinically relevant outcome like post‐endoscopy Barrett's neoplasia remains unknown. Post‐endoscopy Barrett's neoplasia refers to the rate of high‐grade dysplasia or oesophageal adenocarcinoma on repeat endoscopy within one year of an index screening examination revealing non‐dysplastic Barrett's oesophagus or low‐grade dysplasia.AimTo assess correlation between neoplasia detection rate and post‐endoscopy Barrett's neoplasia.MethodsWe performed a systematic search of multiple databases from date of inception to June 2021 to identify cohort studies reporting both neoplasia detection rate and post‐endoscopy Barrett's neoplasia. Data from each study were pooled using a random effects model, and their correlation assessed using meta‐regression. Heterogeneity was assessed and a priori planned subgroup analyses were conducted.ResultsTen studies with 27 894 patients with Barrett's oesophagus were included. The pooled neoplasia detection rate and post‐endoscopy Barrett's neoplasia were 5.0% (95% CI: 3.4%‐7.1%, I2 = 97%) and 19.6% (95% CI: 10.1%‐34.7%, I2 = 96%), respectively. Meta‐regression revealed a statistically significant inverse relationship between the two variables (coefficient −3.50, 95% CI: −4.63 to −2.37, P < 0.01). With every 1% increase of neoplasia detection rate, post‐endoscopy Barrett's neoplasia decreased by 3.50%. Heterogeneity was high despite adjusting for study quality and performing several subgroup analyses.ConclusionWe observed a statistically significant inverse correlation between neoplasia detection rate and post‐endoscopy Barrett's neoplasia. Additional studies are needed to further validate this correlation.
Smoke-Free Policies and 30-Day Mortality Rates for Chronic Obstructive Pulmonary Disease
Hamadi, Hanadi , Stallings‐Smith, Sericea , Apatu, Emma , Peterson, Breck, Spaulding, Aaron , Spaulding, Aaron , Hamadi, Hanadi Y

Mayo Clinic

International Journal of Health Policy and Management | July 18, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.34172/ijhpm.2021.74 | PMID 34380194 Get It

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
Ganesh, Ravindra , Bierle, Dennis M. , Anderson, Ryan J. , Arndt, Lori L., Arndt, Richard , Culbertson, Tracy L, Borgen, Molly J. Destro, Hanson, Sara N. , Kennedy, Brian , Kottke, Brian B, Larsen, Jennifer J., Ramar, Priya , Rosedahl, Jordan K., Seville, Maria Teresa , Speicher, Leigh L. , Tulledge‐Scheitel, Sidna M. , Wilker, Caroline G. , Arndt, Richard F, Destro Borgen, Molly J, Kennedy, Brian D, Tulledge-Scheitel, Sidna M, Razonable, Raymund R , Ganesh, Ravindra , Philpot, Lindsey M. , Razonable, Raymund R.

Mayo Clinic

The Journal of Infectious Diseases | July 17, 2021 | Volume: 224 | Issue: 8 | Pages: 1278-1286

10.1093/infdis/jiab377 | PMID 34279629 Get It

Abstract Background Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the outcomes of patients who received these therapies to identify factors associated with hospitalization and other clinical outcomes. Methods Adult patients who received monoclonal antibody from 19 November 2020 to 11 February 2021 were selected and divided into those who received bamlanivimab (n = 2747) and casirivimab-imdevimab (n = 849). The 28-day all-cause and COVID-19–related hospitalizations were compared between the groups. Results The population included 3596 patients; the median age was 62 years, and 50% were female. All had ≥1 medical comorbidity; 55% had multiple comorbidities. All-cause and COVID-19–related hospitalization rates at 28 days were 3.98% and 2.56%, respectively. After adjusting for medical comorbidities, there was no significant difference in all-cause and COVID-19–related hospitalization rates between bamlanivimab and casirivimab-imdevimab (adjusted hazard ratios [95% confidence interval], 1.4 [.9–2.2] and 1.6 [.8–2.7], respectively). Chronic kidney, respiratory and cardiovascular diseases, and immunocompromised status were associated with higher likelihood of hospitalization. Conclusions This observational study on the use of bamlanivimab and casirivimab-imdevimab in high-risk patients showed similarly low rates of hospitalization. The number and type of medical comorbidities are associated with hospitalizations after monoclonal antibody treatment.
The Impact of Breast Symmetry on Eye Movement and Gaze Pattern: An Eye-Tracking Investigation
Kandelhardt, Chiara, Ehrl, Denis , Kohler, Lukas , Koban, Konstantin Christoph , Giunta, Riccardo E. , Guertler, Anne , Cotofana, Sebastian , Frank, Konstantin , Velthuis, Peter J. , Koban, Konstantin , Cotofana, Sebastian , Moellhoff, Nicholas , Mardini, Samir , Frank, Konstantin

Mayo Clinic

Aesthetic Surgery Journal | July 17, 2021 | Volume: 41 | Issue: 11 | Pages: NP1512-NP1518

10.1093/asj/sjab285 | PMID 34272851 Get It

Abstract Background The objective assessment of beauty remains challenging despite ongoing research efforts. A new method of objectively determining the aesthetic appeal of body features by analyzing gaze patterns and eye movements has recently been investigated. Objectives The objective of this study was to assess, by means of objective eye-tracking technology, differences in the gaze patterns of observers presented with standardized 3-dimensional images showing different degrees of breast asymmetry. Methods A total of 83 Caucasian study participants with a mean age of 38.60 (19.8) years were presented with 5 images depicting varying degrees of breast asymmetry. In addition to the assessment of eye movements, participants were asked to rate the aesthetic appeal and the asymmetry of the breasts on a 5-point Likert scale. Results Overall, the data showed that participants’ rating of the breasts’ aesthetic appeal was inversely related to the level of asymmetry. The mean [standard deviation] time until fixation was shortest for the image depicting the greatest breast asymmetry (50 cc) at 0.77 [0.7] seconds (P &lt; 0.001). In addition, the mammary region was also viewed longest in this image at 3.76 [0.5] seconds (P &lt; 0.001). A volume difference of 35 cc between breasts deflected the observers’ gaze significantly toward the larger of the asymmetric breasts (P &lt; 0.001). Conclusions Surgeons should focus on achieving symmetric breast volume (ie, differences &lt;35 cc between breasts) to avoid noticeable asymmetry with regard to breast size.
Deep neural networks learn by using human-selected electrocardiogram features and novel features
Lerman, Gilad , Friedman, Paul A. , Lerman, Gilad , Attia, Zachi I.

Mayo Clinic

European Heart Journal - Digital Health | July 17, 2021 | Volume: 2 | Issue: 3 | Pages: 446-455

10.1093/ehjdh/ztab060 | PMID 36713603 Get It

Abstract Aims We sought to investigate whether artificial intelligence (AI) and specifically deep neural networks (NNs) for electrocardiogram (ECG) signal analysis can be explained using human-selected features. We also sought to quantify such explainability and test if the AI model learns features that are similar to a human expert. Methods and results We used a set of 100 000 ECGs that were annotated by human explainable features. We applied both linear and non-linear models to predict published ECG AI models output for the detection of patients’ age and sex. We further used canonical correlation analysis to quantify the amount of shared information between the NN features and human-selected features. We reconstructed single human-selected ECG features from the unexplained NN features using a simple linear model. We noticed a strong correlation between the simple models and the AI output (R2 of 0.49–0.57 for the linear models and R2 of 0.69–0.70 for the non-linear models). We found that the correlation of the human explainable features with either 13 of the strongest age AI features or 15 of the strongest sex AI features was above 0.85 (for comparison, the first 14 principal components explain 90% of the human feature variance). We linearly reconstructed single human-selected ECG features from the AI features with R2 up to 0.86. Conclusion This work shows that NNs for ECG signals extract features in a similar manner to human experts and that they also generate additional novel features that help achieve superior performance.
Superior Semicircular Canal Dehiscence Syndrome Following Head Trauma: A Multi‐institutional Review
McCrary, Hilary C. , Babajanian, Eric E. , Patel, Neil S. , Yang, Sara , Kircher, Matthew L., Carlson, Matthew L. , Gurgel, Richard K. , Gurgel, Richard Klaus

Mayo Clinic

The Laryngoscope | July 17, 2021 | Volume: 131 | Issue: 11 | Pages: No page available

10.1002/lary.29751 | PMID 34272884 Get It

ObjectiveTo evaluate patients who become symptomatic from superior semicircular canal dehiscence (SSCD) following head trauma.Study DesignCase series assessing patients presenting with SSCD after a trauma.MethodsA case series was completed assessing patients presenting with SSCD after trauma. Data from three academic medical centers were evaluated, including the following: imaging, videonystagmography (VNG)/vestibular evoked myogenic potential (VEMP) testing, audiometric assessment, and surgical repair. Outcome measures included the following: 1) Description of audio‐vestibular symptoms, 2) mean pre‐ and post‐operative pure tone average (PTA), word recognition score (WRS), and air bone gap (ABG).ResultsA total of 14 patients were included; 86% were male. Approximately 43% were found to have bilateral SSCD on imaging, with 57% of patients pursuing surgical management. The most common presenting symptoms included pulsatile tinnitus (93%), autophony (79%), and hearing loss (64%). Approximately 36% of patients underwent VNG/VEMP testing, with 83.3% of those demonstrating abnormal results. The mean audiometric findings on the symptomatic side included an air‐conduction PTA of 38.0 dB, bone‐conduction PTA of 24.3 dB, WRS of 81%, and ABG of 17.9 dB. Among patients who underwent surgery (57%), there was no significant change in the air‐conduction PTA, bone‐conduction PTA, or WRS (P > .05). However, there was an improvement in the ABG (preoperative = 22.8 dB versus postoperative = 9.7 dB; P = .005).ConclusionHead trauma may be a potentiating event for SSCD syndrome. This study advances the hypothesis that these patients likely have underlying radiographic SSCD prior to their trauma, and a traumatic event increases in intra‐vestibular or intracranial pressures, unmasking SSCD syndrome.Level of Evidence4 Laryngoscope, 131:E2810–E2818, 2021
PRRX1–NCOA1‐rearranged fibroblastic tumour: a clinicopathological, immunohistochemical and molecular genetic study of six cases of a potentially under‐recognised, distinctive mesenchymal tumour
Dermawan, Josephine K. , Azzato, Elizabeth M. , Thangaiah, Judith Jebastin, Gjorgova‐Gjeorgievski, Sandra, Folpe, Andrew L. , Fritchie, Karen , Jebastin Thangaiah, Judith, Folpe, Andrew , Agaimy, Abbas , Dermawan, Josephine K T , Rubin, Brian P.

Mayo Clinic

Histopathology | July 17, 2021 | Volume: 79 | Issue: 6 | Pages: 997-1003

10.1111/his.14454 | PMID 34272753 Get It

AimsPRRX1–NCOA1‐rearranged fibroblastic tumour is a recently described, rare mesenchymal tumour. Only four cases have been previously reported. The aim of this article is to report six additional cases of this unusual mesenchymal neoplasm, with an emphasis on its differential diagnosis.Methods and resultsThe six cases were from three females and three males (age, 20–49 years; median, 42 years). Three tumours were located on the abdominal wall; two from the shoulder/axillary areas, and one on the lateral hip. All presented as slow‐growing subcutaneous nodules, ranging from 26 to 55 mm (median, 40 mm). The tumours consisted of circumscribed, variably cellular nodules composed of relatively bland plump spindled to epithelioid cells arranged singly, in cords, and occasionally in nests, embedded in hyalinised and collagenous stroma. Small hypocellular myxoid zones with ropey collagen fibres were present, as were irregularly dilated, gaping, crescent‐shaped or staghorn‐like thin‐walled vessels, best appreciated at the periphery. Immunohistochemistry for CD34, S100, MUC4 and STAT6 was consistently negative. RNA‐sequencing revealed PRRX1–NCOA1 fusions in all cases. Of the four cases with limited follow‐up (1.5–4 months), none recurred following local surgical excision.ConclusionsThe morphological features of PRRX1–NCOA1‐rearranged fibroblastic tumour overlap with those of RB1‐deficient soft‐tissue tumours, solitary fibrous tumour, and low‐grade fibromyxoid sarcoma/sclerosing epithelioid fibrosarcoma. This differential diagnosis can be resolved with a combination of careful morphological study and the application of a panel of immunostains, although molecular genetic study is most definitive. The natural history of PRRX1–NCOA1‐rearranged fibroblastic tumour appears to be quite favourable, although longer‐term study of a larger number of cases is warranted.
EBV‐positive HIV‐associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features
Chapman, Jennifer R. , Bouska, Alyssa , Zhang, Weiwei , Alderuccio, Juan Pablo , Lossos, Izidore S. , Rimsza, Lisa M. , Maguire, Alanna , Yi, Shuhua , Chan, Wing C. , Song, Joo Y. , Maguire, Alanna , Rimsza, Lisa M , Song, Joo Y , Bouska, Alyssa , Vega, Francisco , Maguire, Alanna

Mayo Clinic

British Journal of Haematology | July 17, 2021 | Volume: 194 | Issue: 5 | Pages: 870-878

10.1111/bjh.17708 | PMID 34272731 Get It

Summary Even in the era of highly active combination antiretroviral therapy (cART), patients with HIV have a disproportionate risk of developing aggressive lymphomas that are frequently Epstein‐Barr virus (EBV)‐related. Here, we investigate HIV‐associated diffuse large B‐cell lymphoma (HIV‐DLBCL) and compare EBV‐positive and EBV‐negative cases. HIV‐DLBCL were identified from two academic medical centres and characterised by immunohistochemistry, EBV status, fluorescence in situ hybridisation, cell of origin determination by gene expression profiling, and targeted deep sequencing using a custom mutation panel of 334 genes. We also applied the Lymphgen tool to determine the genetic subtype of each case. Thirty HIV‐DLBCL were identified, with a median patient age of 46 years and male predominance (5:1). Thirteen cases (48%) were EBV‐positive and 14 (52%) EBV‐negative. Nine of the 16 tested cases (56%) had MYC rearrangement, three (19%) had BCL6 (two of which were double hit MYC / BCL6 ) and none had BCL2 rearrangements. Using the Lymphgen tool, half of the cases (15) were classified as other. All HIV‐DLBCL showed mutational abnormalities, the most frequent being TP53 (37%), MYC (30%), STAT3 (27%), HIST1H1E (23%), EP300 (20%), TET2 (20%), SOCS1 (17%) and SGK1 (17%). EBV‐negative cases were mostly of germinal centre B‐cell (GCB) origin (62%), showed more frequent mutations per case (a median of 13·5/case) and significant enrichment of TP53 (57% vs. 15%; P = 0·046), SGK1 (36% vs. 0%; P = 0·04), EP300 (43% vs. 0%; P = 0·02) and histone‐modifying gene (e.g. HIST1H1E , HIST1H1D , 79% vs. 31%; P = 0·02) mutations. EBV‐positive cases were mostly of non‐GCB origin (70%), with fewer mutations per case (median 8/case; P = 0·007), and these tumours were enriched for STAT3 mutations ( P = 0·10). EBV‐positive cases had a higher frequency of MYC mutations but the difference was not significant (36% vs. 15%; P = 0·38). EBV‐association was more frequent in HIV‐DLBCLs, arising in patients with lower CD4 counts at diagnosis (median 46·5 vs. 101, P = 0·018). In the era of cART, approximately half of HIV‐DLBCL are EBV‐related. HIV‐DLBCL are enriched for MYC rearrangements, MYC mutations and generally lack BCL2 rearrangements, regardless of EBV status. Among HIV‐DLBCL, tumours that are EBV‐negative and EBV‐positive appear to have important differences, the latter arising in context of lower CD4 count, showing frequent non‐GCB origin, lower mutation burden and recurrent STAT3 mutations.